Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mensodol
- Development stage
- Unknown
- Lead developer
- Anthus Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mensodol is an oral combination medication developed and marketed by Anthus Pharmaceuticals, primarily indicated for the relief of symptoms associated with premenstrual syndrome (PMS) and dysmenorrhea. The formulation contains acetaminophen (325 mg), a non-salicylate analgesic and antipyretic that provides pain relief by inhibiting prostaglandin synthesis, and pamabrom (25 mg), a mild diuretic that helps reduce bloating, water retention, and associated discomfort. It is positioned within Anthus Pharmaceuticals' prescription product portfolio in India as a solution for menstrual health.
- Brand names
- Mensodol
- Other names
- Pamabrom + AcetaminophenPamabrom + Paracetamol
02
Targets
ADOR (Adenosine receptors)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Mensodol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mensodol.